Foundayo's fourth-week IQVIA print landed Friday at 7,335 U.S. prescriptions — up roughly 31 percent off the 5,612 fills of week three but still well short of the trajectory required to keep RBC's $1.4 billion full-year model on the page. [1] [2] The paper's May 7 brief on the 24x gap between Foundayo and the Wegovy oral pill named the binary the print would test. The compression came in modestly: 134,000 oral-Wegovy scripts the same comparator week against 7,335 Foundayo scripts is roughly 18x — meaningful, but not the kind of inflection that converts the 24x to a single digit by week 12. [2]

The bar is the bar RBC's Trung Huynh set in the open. "By week 12, we would expect Foundayo to reach more than 90,000 weekly prescriptions to remain on track for average annual sales expectations of about $1.4 billion," Huynh wrote on the week-three print. [3] The week-four read tightens the math: Foundayo would now need to roughly double weekly script volume every two weeks for eight weeks to clear 90,000 by week 12. Yesterday's paper carried the Wegovy pill at the same week-16 mark with 1.3 million weekly prescriptions — the comparator stays at 80 percent naive share inside Q1. The Q2-consensus check is more immediate: Huynh has put a $160 million Q2 sales target at roughly 22,000 prescriptions per week. [2] Foundayo is at one-third of that.

The two structural drags are the same drags. First, the fasting requirement. Foundayo requires a fasting window before eating; oral semaglutide does not. The instruction carries cost in adherence — every prescriber who has handled both molecules sees the gap in patient diaries. Second, payer access. Two of the three largest pharmacy benefit managers had commercial coverage in place by April 30; the third has not. [4] Wegovy oral carries TrumpRx self-pay coverage at announced $25 and $149 tiers; Foundayo had not appeared on the federal portal as of last week. The payer split lands inside a launch window where Wegovy entered with pent-up demand and Foundayo arrived after the conversion cohort had largely cleared.

The data itself sits inside an asterisk. Two analysts cited by TradeVae flagged "potential gaps in telehealth prescription coverage within the IQVIA dataset, which could cause weekly Foundayo prescription counts to fluctuate as reporting samples adjust." [2] Lilly's launch architecture leans heavily on LillyDirect (the company's own telehealth-and-mail-order channel) and on telehealth partnerships that prescription-tracking services may undercount or mistime. The 7,335 number, in plainer terms, is a directional read on the visible retail and partial telehealth signal — the actual exposure could be 10 percent higher, possibly more, depending on which weeks' telehealth fills are settled into the panel. The consensus-Q2 math does not move much under that adjustment.

What does move is the prescriber base. Lilly executives told analysts April 30 that Foundayo had been used by more than 20,000 patients with 8,000 prescribers, a third of whom had not previously written an oral GLP-1 prescription. [5] The prescriber-expansion read is the optimistic frame: Foundayo is reaching new physicians who did not write Wegovy oral, and that base has not yet converted into accelerating script volumes. The pessimistic frame is the same number read inversely: 8,000 prescribers in week four against 7,335 weekly fills means roughly 0.9 fills per prescriber per week. The prescriber base is wide; the per-prescriber prescribing pattern is shallow. Wegovy's pattern was the opposite — fewer prescribers initially, deeper per-prescriber prescribing.

Novo's CEO call Thursday made the upstream Copenhagen tape unavoidable for the Friday-Saturday U.S. read. Lars Fruergaard Jørgensen called the Wegovy pill a "record-breaking start" — the language Novo has now used for two consecutive quarters on a launch that crossed two million scripts since January 5. The framing puts the Foundayo Q2 model under pressure not because Foundayo is failing in absolute terms — 7,335 scripts in week four is faster than Saxenda's launch a decade ago — but because the comparator on the same shelf is running at scale that bends the analyst model.

What the paper now tracks: whether any sell-side note revises the FY $1.4 billion model within 48 hours of the print, and whether Lilly's response on the next IR update names a path to 22,000 weekly that does not depend on the third PBM coming online. The Day 1 weekend read is that the print compressed the 24x gap to roughly 18x. The chart, not the press release, is the call. The chart says the bar is harder this Friday than it was last Friday.

-- NORA WHITFIELD, Chicago